Family

Loading Family data...

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)	101 RUE DE TOLBIAC CEDEX 13 PARIS 75654
UNIVERSITE PAUL SABATIER TOULOUSE III	118 ROUTE DE NARBONNE TOULOUSE CEDEX 9 31062
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE	2 RUE VIGUERIE HÔTEL-DIEU PONT NEUF TOULOUSE 31300

International Classification(s)

• G01N:INVESTIGATING OR ANALYSING MATERIALS BY DETERMININ....

• 2013 Application Filing Year
• G01N Class
• 9056 Applications Filed
• 7640 Patents Issued To-Date
• 84.37 % Issued To-Date

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
Desmoulin, Franck	Toulouse Cedex 4, FR	5	0
# of filed Patents : 5 Total Citations : 0
Galinier, Michel	Toulouse Cedex 4, FR	4	0
# of filed Patents : 4 Total Citations : 0
Rouet, Philippe	Toulouse Cedex 4, FR	9	1
# of filed Patents : 9 Total Citations : 1
Smih-Rouet, Fatima	Toulouse Cedex 4, FR	2	0
# of filed Patents : 2 Total Citations : 0

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

• 0 Citation Count
• G01N Class

• 0 % this patent is cited more than
• 10 Age

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date
11.5 Year Payment	$7400.00	$3700.00	$1850.00	Feb 6, 2027

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge - 11.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

Full Text

US Patent Application No: 2015/0219,669

Diagnostic of Heart Failure

---

Abstract

---

The invention relates to a method for classifying a patient at risk for heart failure, wherein said method comprises the steps of (i) measuring the concentration of IGFBP2 in a sample obtained from said patient and (ii) comparing the concentration of IGFBP2 measured in step (i) to a control value derived from the concentration of IGFBP2 in samples from patients who are at particular stages of heart failure and/or to a control value derived from the concentration of IGFBP2 in blood samples from healthy patients.

---

 

---

Description

---

Claims

---

Claims data not available

---

Legal Events

• No Legal Status data available.